International Myeloma Foundation’s Post

Dr. Shah's knowledge about nutrition and myeloma is remarkable. I encourage you to tune into this informative FB Live. #MyelomaActionMonth

TOMORROW, Andrew Weil Center for Integrative Medicine's Associate Director of Fellowship Dr. Lise Alschuler, ND, FABNO, and Karolyn Gazella, co-authors of "The Definitive Guide to Thriving After Cancer" and "The Definitive Guide to Cancer," will introduce you to ways to reduce the risk of #cancer and #CancerRecurrence by optimizing the health of 5 key pathways: #immunity, #inflammation, #insulin regulation, #detoxification, and #HormonalBalance. ⭐ FREE RSVP: https://lnkd.in/eZiyTEC7 👈 (includes recording) Learn which #lifestyle strategies — such as #diet, #mindbody practices, physical activity, and key #supplements — can transform your body into one that cancer doesn’t like. There will be a live Q&A at the end! #CancerSurvivors #CancerRisk #CancerPrevention #IntegrativeMedicine #IntegrativeOncology #CancerPrevention #BreastCancer #ProstateCancer #Melanoma #ThyroidCancer

A recent study using #Mendelian randomization has revealed the causal relationship between 14 site-specific cancers and venous #thromboembolism (VTE). The study found that non-Hodgkin's #lymphoma may increase the risk of VTE, while #melanoma decreases the risk. This research sheds light on the complex interplay between cancer and VTE, providing valuable insights for patient care and management. Read more: https://lnkd.in/gg4GvFKa #CancerResearch #VTE #BRAF #MendelianRandomization #MedicalInsights #sciopen #TUP🧬🔬

Thank you, Mia Levy, for the insightful post from Foundation Medicine. The power of #DataScience in #Oncology is truly remarkable. It’s exciting to witness the continued evolution of precision medicine in prostate cancer, showcasing how data science and informatics are driving biomarker discoveries, advancing genomic testing, and introducing new diagnostic tools that enable less invasive treatments for patients with advanced disease. The discussion around liquid biopsy and the use of ctDNA tumor fraction to complement tissue testing is especially noteworthy, as it seems to address a critical clinical need—offering more confidence in interpreting negative results and providing an additional biomarker to assess treatment response. The potential of longitudinal ctDNA monitoring tools to track tumor response over time is another fascinating advancement. It could significantly enhance how clinicians assess and adjust treatment in real-time, particularly in challenging cases where traditional methods may fall short. Additionally, the narrative highlighting the FDA’s approval of PARP inhibitors and checkpoint inhibitors is a great example of how a deeper understanding of prostate cancer’s genetic and molecular characteristics is leading to more targeted and effective treatments. Foundation Medicine’s CGP tests, which identify key biomarkers, underscore the growing reliance on advanced testing to guide treatment decisions, solidifying CGP as a crucial tool in modern oncology—at least, in my humble opinion :) I hope to continue this discussion on #PrecisionOncology next month at our 22nd Cancer Center Informatics Society Symposium in Charleston. See you all there! https://lnkd.in/gtFitkSW

Join me (Dr. Malathi Acharya) as I debunk the myth: "If no one in my family has had cancer, am I risk-free?" In this video, I will reveal the truth about cancer risks and the importance of personalized care. Check out the video and learn more. Contact us at info@ayur.today to explore personalized holistic cancer care options. Ayur Integrative Medicine #CancerAwareness #MythBusting #HolisticHealth #CancerMyths #CancerAwareness #DrMalathiAcharya #HealthEducation #CancerPrevention #SugarAndCancer #MythBusting

Explore the latest advancements in clinical guidelines and their implications for #MultipleMyeloma clinical pathways through our complimentary CME webcast. Understand the critical role of biomarker testing and its influence on the delivery of cancer care and quality metrics. Stream now: https://okt.to/OgpMXs

Explore the latest advancements in clinical guidelines and their implications for #MultipleMyeloma clinical pathways through our complimentary CME webcast. Understand the critical role of biomarker testing and its influence on the delivery of cancer care and quality metrics. Stream now: https://okt.to/con8Fp

🔬 On 𝐖𝐨𝐫𝐥𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐃𝐚𝐲, we highlight the critical importance of research in transforming the future of cancer care. ⚗The 𝐄𝐋𝐌𝐔𝐌𝐘 project is focused on tackling #multiplemyeloma, a rare but aggressive blood cancer. With groundbreaking #research, we aim to develop more targeted treatments and improve the quality of life for patients affected by this disease. 🌍 By fostering #collaboration across Europe’s top research institutions and medical experts, we’re accelerating progress toward innovative solutions. Every discovery brings us one step closer to better treatment outcomes. 💡 Research is key to making this vision a reality. #MissionCancer #HorizonEU #WorldCancerResearchDay #MultipleMyeloma #EUfunded #CancerResearch 

Staying informed about the dynamic field of #rectalcancer is crucial for healthcare professionals and patients alike. ✅ Stay up-to-date with a comprehensive Q&A session from Director of Research for the Digestive Disease Institute, Marylise Boutros, MD providing insight into the evolving landscape of rectal cancer management. https://cle.clinic/4apuCTQ #RectalCancer #CancerCare

ICYMI: our Chief Medical Officer and Executive VP of R&D, Dr. Richard Chen, was featured on a local FOX KTVU2 News segment highlighting our whole-genome based, liquid biopsy assay, NeXT Personal®. NeXT Personal can detect very small traces of cancer from a blood test from patients with cancer and help predict relapse months, sometimes even years ahead of imaging. In a study from the The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust featuring 78 patients with early-stage breast cancer, 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Take a look at the segment that aired last month: https://bit.ly/4bOrkJE. #PrecisionOncology #ASCO24 #LiquidBiopsy #CancerResearch